Tyrosine kinase inhibitorFDA-approvedFirst-line
Iressa
Generic name: gefitinib
How it works
Blocks the activity of a protein called EGFR, which is involved in the growth and spread of cancer cells.
Cancer types
Lung Cancer— EGFR-mutated
Efficacy
In clinical trials, patients with EGFR-mutated lung cancer treated with Iressa had a response rate of approximately 70% and a median progression-free survival of around 2 months.
Side effects
Mild
Most people tolerate this treatment well. Side effects are generally manageable and do not require stopping treatment.
Evidence from research
| Study | Cancer type | Stage | Efficacy | |
|---|---|---|---|---|
| New Biomarker Identified for Lung Cancer Treatment Response | Lung Cancer | lab-study | — | Source → |
| New Nanoparticle Formulation Enhances Cancer Drug's Effectiveness | Lung Cancer | lab-study | The nanosuspension showed a 33.8% higher inhibition rate than the physical mixture after 72 h. | Source → |
| Combining Traditional Chinese Medicine with Gefitinib May Help Treat Lung Cancer | Lung Cancer | lab-study | The combination therapy suppressed both the clonogenic ability and the combined processes of migration and proliferation in H1975 cells. | Source → |
| Bufalin May Help Overcome Lung Cancer Resistance to Certain Treatments | Lung Cancer | lab-study | — | Source → |
| Gefitinib Resistance in Lung Cancer: A New Pathway Discovered | Lung Cancer | lab-study | — | Source → |
| Berberine May Help Protect Liver from Gefitinib Side Effects | Lung Cancer | lab-study | — | Source → |
This information is provided for general education only and is not medical advice. Always consult a qualified healthcare professional before making treatment decisions.